MGIC Investment Corporation (NYSE:MTG) [Trend Analysis] climbed reacts as active mover, shares an increase 0.53% to traded at $10.49 and the percentage gap between open changing to regular change was 0.10%. MGIC Investment Corp. (MTG) expected to write slightly less new insurance in 2017 compared to 2016 reflecting the current market conditions and a smaller origination market, however, when combined with an improvement in annual persistency the company expects that insurance in force portfolio will continue to grow.
The company noted that it will continue to focus on maintaining industry leading expense ratio and further improving capital structure for the betterment of shareholders.Further the company anticipates that the number of new mortgage delinquency notices, claims paid and delinquency inventory will continue to decline and we are well positioned to provide credit enhancement and low down payment solutions to lenders, GSEs and borrowers, now, and in the future. The firm past twelve months price to sales ratio was 3.38 and price to cash ratio remained 12.97. As far as the returns are concern, the return on equity was recorded as 14.00% and return on investment was 36.00% while its return on asset stayed at 5.80%. The firm has total debt to equity ratio measured as 0.40.
Shire plc (NASDAQ:SHPG) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.79% to close at $162.81 with the total traded volume of 306713 shares. Shire plc (SHPG) declared that U.S. Food and Drug Administration has acknowledged receipt of the Class 2 resubmission of a New Drug Application or NDA for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation.SHP465 is being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder or ADHD.
The FDA is expected to provide a decision on or around June 20, 2017, the designated Prescription Drug User Fee Act (PDUFA) action date.Shire resubmitted the NDA for SHP465 in response to the Approvable Letter from the FDA (May 18, 2007) that requested additional clinical studies and classified the response as a Class 2 resubmission with a review goal of six months. The firm has institutional ownership of 23.30%, while insider ownership included 0.10%. Its price to sales ratio ended at 5.21. SHPG attains analyst recommendation of 1.70 with week performance of -3.22%.